33 results about "Diabetic rat" patented technology

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and more particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of diabetes. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce blood glucose levels in type 2 diabetic rats and increase serum insulin levels and insulin sensitivity index in rats. Moreover, the compound combination drug for treating diabetes is an existing TCM preparation, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pills are easy to carry and convenient to take.

The invention relates to the technical field of medical biological materials, in particular to hydrogel capable of self-adaptively releasing exosomes and a preparation method and application thereof.The hydrogel comprises a precursor, a buffer solution and the exosomes, the precursor is dissolved in the buffer solution to form a matrix of a three-dimensional network structure, and the exosomes are loaded in the three-dimensional network structure of the matrix; the precursor comprises HA-ADH and OHA-TK-CP, and the mass ratio of the HA-ADH to the OHA-TK-CP is (1: 5)-(1: 1); in-vivo and in-vitro research results show that the hydrogel has excellent self-repairing capability, remarkable antibacterial activity, efficient exosome release and effective ROS (reactive oxygen species) reduction capability, the wound healing of MRSA-infected diabetic rats is accelerated by the synergistic anti-inflammatory effect and tissue regeneration promotion effect of the hydrogel, and scars are relatively small after the wound healing; the preparation method is simple to operate, mild in reaction condition and beneficial to large-scale production.

The invention provides a process for preparing a Biochanin A (BCA)-loaded hydroxypropyl methyl cellulose (HPMC) hydrogel aimed at promoting wound healing in diabetic patients. The hydrogel is prepared by dispersing HPMC in distilled water, followed by dissolving BCA into the mixture with continuous stirring, then storing under refrigeration. The therapeutic potential of Biochanin A (BCA) in promoting wound healing, is evaluated in rats induced with diabetes. The results showed that the BCA-loaded hydrogel accelerates diabetic wound repair by boosting antioxidant defenses via upregulating Nrf2 and related enzymes, suppressing inflammatory markers such as IL-1β, IL-6, TNF-α, COX-2, and TLR4, and stimulating angiogenesis through increased expression of TGF-β1, VEGF-A, and PDGFR. It promotes faster wound contraction, re-epithelialization, collagen deposition, granulation tissue formation, and neovascularization, potentially reducing the risk of complications like limb amputation. The invention offers a promising therapeutic approach for treating chronic diabetic wounds with improved healing outcomes.

The present application belongs to the field of biological medicine, and relates to an in-situ spraying particle-gel composite as well as a preparation method and application thereof. The present application prepares a drug-loaded particle-gel composite material, which can be rapidly gelled in-situ in the form of spraying. In a wound infection model of diabetic rats, the composite material exhibits good photothermal activation TRPV1 channel-mediated local analgesia, as well as anti-inflammatory, antibacterial, antioxidant, hemostatic and wound healing-promoting multifunctional therapeutic effects. Through in-vitro and in-vivo material characterization, as well as histopathological examination of animal experiments, it is confirmed that the composite gel material has good biological safety and degradability, and is a local anesthetic biomaterial preparation which is expected to be clinically transformed for chronic wound analgesia and healing-promoting therapeutic effects.

The invention belongs to the technical field of construction of experimental animal models, and particularly relates to a construction method and application of a recombinant inbred line type 2 diabetes mellitus rat model, in parent rats, female rats are SD (fa + / +) or Wistart (fa + / +), male rats are Zucker (fa + / -), heterozygote (fa + / -) female rats in filial generations obtained through hybridization are backcrossed with male parents until an F6 generation, and the female rats and the male rats are subjected to cross breeding to obtain the recombinant inbred line type 2 diabetes mellitus rat model. And hybridizing the F6 generation heterozygote (fa < + / ->) female rat with the F6 generation heterozygote (fa < + / ->) male rat to obtain a homozygote (fa <- / ->) SD / Zucker or Wistart / Zucker rat which is the recombinant inbred line type 2 diabetes mellitus rat. The obtained rats cannot express functional leptin receptors, have hyperappetite and autonomous polydipsia and polyphagia, and are very in line with real occurrence scenes of type 2 diabetes mellitus caused by overnutrition of diet under normal diet conditions of human beings.

The present invention provides a method for constructing a rat model simulating the clinical characteristics of peripheral arterial disease, comprising the following steps: Step 1: A unilateral femoral artery of a diabetic rat is ligated with an Ameroid constrictor ring, and the rat is raised for a period of time; Step 2: The femoral artery of the rat surviving after being raised in Step 1 is ligated. In Step 1 and Step 2, the ligation of the Ameroid constrictor ring and the femoral artery ligation are both located on the same side femoral artery of the rat. The present invention establishes a chronic limb ischemia animal model conforming to the clinical characteristics of peripheral arterial disease. The present invention intends to induce type 2 diabetes in rats by feeding them with a high-fat and high-sugar diet, use an Ameroid constrictor ring on the femoral artery to cause progressive limb ischemia, and then ligate the femoral artery to cause vascular occlusion to simulate critical limb ischemia. The "staged" chronic limb ischemia in diabetic rats provides a suitable animal model for the basic research of peripheral arterial disease.

The present application relates to a kind of porous scaffold for repairing bone defect loaded with black phosphorus active oxygen elimination and slow-release drug and its preparation method;The scaffold includes the amino cation polymer grafted with the phenylboronic acid (PBA) and cyclodextrin (CD) that can eliminate active oxygen, black phosphorus nanosheet (BP) and scaffold material poly (lactic acid-glycolic acid) (PLGA).The porous scaffold loads a large number of black phosphorus nanosheet that can be hydrolyzed into bone repair nutrients, and the porous structure provides sufficient space for cell migration and growth, realizes the good repair of bone.Active oxygen elimination ability, can eliminate active oxygen in diabetic microenvironment.In addition, cyclodextrin can load a variety of drugs, such as osteogenic differentiation induction drug, and realize the slow release of drug.The porous scaffold has good biocompatibility, and the degradation product is harmless to human body, can be used for the tissue repair of bone defect, can be widely applied in the field of biological medicine and tissue engineering, and has been proved to have good repair ability in the diabetic rat skull defect model.

The invention belongs to the technical field of fermentation, and particularly relates to medicinal and edible fermentation liquor with a blood sugar reducing effect as well as a preparation method and application of the medicinal and edible fermentation liquor. The fermentation liquor is prepared from the following components in parts by weight: 50 to 75 parts of fructus corni, 45 to 65 parts of stigma croci, 40 to 60 parts of fructus physalis pubescentis, 35 to 50 parts of rumex hanus, 13 to 20 parts of an enzyme preparation and 0.17 to 0.25 part of a leavening agent. The obtained fermentation liquor has the effect of inhibiting alpha-glucosidase through in-vitro verification, the fasting blood glucose level of rats with type 2 diabetes mellitus can be reduced through rat experiment verification, and the effect of reducing blood glucose can be achieved through a PI3K / Akt channel.

The invention discloses eye drops for treating vascular hyperplasia of eyes and a preparation method of the eye drops, and belongs to the technical field of biological pharmacy. The eye drops comprise a recombinant human angiostatin protein, an endostatin protein and a pharmaceutically acceptable carrier, wherein the recombinant human angiostatin protein and the endostatin protein are used for preparing the eye drops. Experiments show that the eye drops show remarkable vascular inhibition activity in a chick embryo chorioallantoic membrane model and a diabetic rat retina hyperplasia model, and the two proteins are combined for use to achieve a synergistic effect; the invention provides a safe and effective new way for local treatment of ocular vascular hyperplasia diseases.

The invention discloses a targeting stem cell exosome composition and application thereof in treating diabetic foot ulcer. According to the composition, a mesenchymal stem cell exosome is modified through genetic engineering, specific targeting fusion polypeptide is expressed on the surface of the mesenchymal stem cell exosome, anti-inflammatory miR-146a and a pro-angiogenic factor VEGF are loaded, and then the mesenchymal stem cell exosome is compounded with temperature-sensitive hyaluronic acid hydrogel to form a sustained release system. The sequence of the fusion polypeptide is as shown in SEQ ID NO: 1, and the targeting of exosomes to diabetic inflammation parts is remarkably improved; the stability of miR-146a is enhanced through chemical modification, and the miR-146a cooperates with VEGF to inhibit inflammation and promote revascularization. In-vitro experiments show that the composition reduces the levels of TNF-alpha and IL-6 by 85% and 88% respectively, and the cell migration rate reaches 99.3%; in-vivo experiments show that the wound healing rate of diabetic rats reaches 99.6% on the 14th day, and the collagen deposition area proportion is increased to 77.5%. The invention has targeting property, function synergy and slow release performance, and provides an efficient treatment strategy for diabetic foot ulcer.

The application belongs to the field of biomedical materials, and discloses a multifunctional hydrogel suitable for diabetic wound healing. The hydrogel is compounded by HA-Tris, EPL-Cpb and MXene / Mn composite nanoparticles in a mass ratio of 2:1:(0-0.2), and is rapidly crosslinked in 1 min through a triple mechanism, with a crosslinking efficiency increased by more than 80% compared with traditional methods and a yield of more than 99.5%. The application realizes chemical-photothermal dual-mode antibiosis through precise optimization of the ratio and reaction conditions and the function synergy of the components, with an inhibition rate of 96.86% and 97.23% for Escherichia coli and Staphylococcus aureus, which is increased by more than 62% compared with traditional silver-containing dressings; the hydrogel has a ROS clearance rate of 92.5% and an in-situ oxygen production rate increased by 58% compared with traditional methods, and can efficiently stop bleeding within 30 s, with a blood loss reduced by 90.3% compared with the blank group. The hydrogel has excellent biocompatibility and can comprehensively improve the pathological microenvironment of diabetic wounds, shortening the healing period of full-thickness skin wounds of diabetic rats from 21 days to 10 days, and providing a new and efficient biomedical material for the treatment of diabetic wounds.

The invention relates to application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes, and belongs to the technical field of photomedicine. The invention provides application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes. According to the invention, a diabetic rat model is established, near-infrared light and blue light are adopted to carry out phototherapy on diabetic rats, and blood sugar and blood fat related indexes of the diabetic rats and changes of different tissue forms and behaviors of the rats are measured; results show that the near-infrared light and the blue light can effectively improve blood sugar and blood fat related indexes of the rats after phototherapy of the rats, and can also improve tissue morphology and cognitive behaviors of the diabetic rats, which indicates that the phototherapy of the near-infrared light or the blue light has the effects of treating diabetic blood sugar and cognition, can reduce dependence of patients on medicines, and can improve the curative effect of the patients on diabetes mellitus. And new experimental basis and theoretical support are provided for clinical non-drug intervention of diabetes.

The invention provides a multifunctional polyrotaxane hydrogel FDS. NO loaded on the FDS hydrogel has the capability of promoting cell migration, proliferation and angiogenesis at the same time. The FDS hydrogel can inhibit the activation of a downstream pathway by adsorbing extracellular DNA (cfDNA), thereby reducing the release of inflammatory factors. Animal experiments further prove that the FDS hydrogel not only can sterilize and promote cell proliferation and reconstruction of a diabetic wound area, but also can promote angiogenesis of a diabetic rat wound. Therefore, the FDS hydrogel has remarkable advantages in diabetes wound management.

The application discloses a novel brown algae polysaccharide SARP for promoting healing of diabetic ulcers and a preparation and application thereof. A novel SARP is obtained through Sephacryl S-300 / HR gel column separation and purification, and the molecular weight of the SARP is about 45.4 kDa, which is composed of mannuronic acid (76.56%), guluronic acid (18.89%) and a small amount of glucuronic acid (4.55%). Compared with alginate separated from other brown algae, the SARP has a higher content of mannuronic acid. The SARP shows a better in-vitro antioxidant capacity, and can obviously reverse the cell damage of HUVECs caused by H2O2 and high sugar in the HUVECs. In addition, the SARP can promote the migration and tubular formation of the HUVECs. In-vivo experiments further show that the SARP can promote the healing of diabetic ulcer in rats, and can reduce the oxidative stress, inflammation level and lipid disorder in the rats. The SARP has a simple purification route, can be prepared in a large amount, and is a very promising novel drug for treating diabetic foot ulcers.

The invention discloses a method for establishing a type II diabetes mellitus rat model in the technical field of biology, which comprises the following steps of: regulating and controlling dynamic pathology evolution, reproducing the natural disease course of type II diabetes mellitus in stages from insulin resistance-beta cell injury-multi-organ complications-flora intervention and nerve regulation, and establishing a type II diabetes mellitus rat model. The animal model is used for overcoming the defects of a traditional model in the aspect of simulating complex pathological characteristics, the animal model capable of more comprehensively reproducing the multi-dimensional pathological characteristics of the human type II diabetes mellitus is constructed by optimizing an induction strategy and integrating multi-factor intervention, and a more reliable tool is provided for diabetes mellitus mechanism research and drug development.

The invention belongs to the field of experimental animal models, and particularly relates to a feed for inducing type II diabetes mellitus and application thereof, the feed comprises the following components by weight: 450-550 parts of conventional components, 10-150 parts of rapeseed oil with trans fatty acid content of 63-67 g / L, 30-170 parts of lard, and 170-180 parts of sucrose; the conventional components consist of the following components in parts by weight: 200 parts of casein, 3 parts of L-cystine, 72.8 parts of corn starch, 100 parts of maltodextrin, 50 parts of cellulose, 25 parts of soybean oil, 10 parts of trace elements, 10 parts of vitamins, 2 parts of choline bitartrate, 0.05 part of a coloring agent, 13 parts of calcium hydrophosphate, 5.5 parts of calcium carbonate and 16.5 parts of potassium citrate. Compared with a commercially available feed D12451, the feed provided by the invention can efficiently induce a stable and typical type II diabetes rat model.

The application belongs to the technical field of traditional Chinese medicine preparation, and discloses a traditional Chinese medicine composition, a preparation method and application thereof. One of the traditional Chinese medicine compositions comprises the following raw materials in parts by weight: Cyclobalanopsis glauca 50-80 parts, tartary buckwheat 30-50 parts, polygonatum 30-50 parts, honeysuckle 30-50 parts, Poria cocos 10-20 parts, gordon euryale seed 10-20 parts, lotus seed 10-20 parts, medlar 10-20 parts, angelica 10-20 parts, yam 5-15 parts, hawthorn 5-15 parts, and sour jujube seed 5-15 parts. The compound preparation has a good blood glucose-lowering effect, can correct the lipid metabolism disorder of diabetic rats, and reduce liver function damage, has a certain protective effect on the liver, and can be applied to the preparation of a medicine for treating non-alcoholic fatty liver. On this basis, in addition to adding part of the medicinal materials, the traditional Chinese medicine composition can also be applied to the preparation of a medicine for treating chronic obstructive pulmonary disease and a medicine for treating bacterial pneumonia.

The invention belongs to the field of development and utilization of beautiful millettia roots, and particularly relates to a beautiful millettia root flower extract and a preparation method and application thereof. Fresh flower buds in the initial flowering period of beautiful millettia roots are adopted as raw materials, fermentation liquor is prepared through fermentation of lactobacillus, lactobacillus casei and lactobacillus acidophilus, after sterilization, cellulase, pectin lyase and cellobiohydrolase are added for enzymolysis, enzymatic hydrolysate is obtained, after enzyme deactivation of the enzymatic hydrolysate, alcohol precipitation is conducted to remove precipitates, and the finished product is obtained. The prepared millettia specisoa flower extract can reduce blood sugar of rats with type 2 diabetes mellitus and regulate intestinal flora of the rats, and a new candidate medicine is provided for treatment of diabetes mellitus.

The invention provides a magnesium oxide-loaded asymmetric short fiber aerogel scaffold as well as a preparation method and application thereof, and belongs to the technical field of tissue engineering materials. The preparation method comprises the following steps: adding MgO nanoparticles into a PLLA / Gelatin solution, and carrying out electrostatic spinning, crushing, freeze drying and crosslinking to obtain the porous short fiber aerogel scaffold (GP-coated MgO). The GP-coated MgO aerogel stent has a three-dimensional short fiber structure, and can release loaded MgO nanoparticles in a progressive and continuous manner while wound exudate is slowly absorbed. In-vivo and in-vitro experiments prove that the GP-coated MgO aerogel scaffold has biocompatibility and is very effective in the aspects of inhibiting inflammatory response and slowing down cell senescence. In addition, the GP-coated MgO significantly accelerates vascular reconstruction and epithelization, and promotes wound repair at the skin defect position of a diabetic rat.

The invention belongs to the technical field of functional food, and particularly relates to a composition beneficial to maintaining the healthy level of blood sugar and a preparation method and application of the composition. The composition helpful for maintaining the healthy level of blood sugar is prepared from the following components in parts by weight: 5-25 parts of fermented soya bean powder, 1-10 parts of cinnamon powder and 1-10 parts of emblic leafflower fruit powder. The cinnamon powder, the fermented soya bean powder and the emblic leafflower fruit powder in a specific dosage relationship are matched, so that the cinnamon powder, the fermented soya bean powder and the emblic leafflower fruit powder generate a synergistic interaction effect. Experiments prove that the composition provided by the invention can improve the alpha-glucosidase inhibition rate, greatly reduce the fasting blood glucose and insulin resistance index of diabetic rats, and contribute to maintaining the healthy level of blood glucose.

This invention belongs to the field of experimental animal model construction technology, specifically relating to the construction method and application of a recombinant inbred type 2 diabetic rat model. The parent rats are SD (fa+ / +) or Wistar (fa+ / +) females and Zucker (fa+ / -) males. Heterozygous (fa+ / -) female offspring are backcrossed with the fathers until the F6 generation. Then, F6 heterozygous (fa+ / -) female rats are crossed with F6 heterozygous (fa+ / -) male rats. The resulting homozygous (fa- / -) SD / Zucker or Wistar / Zucker rats are the recombinant inbred type 2 diabetic rats. The rats obtained by this invention do not express functional leptin receptors, exhibit hyperphagia, and spontaneous polydipsia and polyphagia, which closely resembles the real-world scenario of type 2 diabetes caused by overnutrition under normal dietary conditions in humans.

The present invention belongs to the field of biomedical technology, and particularly relates to the application of nacre polypeptide Nacrein-LP20 in the preparation of a drug for promoting wound healing. The amino acid sequence of nacre polypeptide Nacrein-LP20 is shown in SEQ ID NO: 1. Nacre active polypeptide Nacrein-LP20 has strong ability to scavenge DPPH free radicals and hydroxyl free radicals, has excellent antioxidant activity, can significantly promote the proliferation of HaCaT cells in a high-glucose environment, and promote its migration and repair in a high-glucose environment; it has a significant effect on promoting the healing of full-thickness excisional wounds in normal rats and diabetic rats.

The invention provides a preparation method of medical titanium of a silicon dioxide and Prussian blue nano-particle composite coating with multiple biological functions and a medical titanium product obtained by the method aiming at the defects that an existing titanium implant surface modification technology is single in function and difficult to adapt to a complex pathological environment. The invention also discloses application of the medical titanium product in a diabetic rat maxilla implantation experiment.

The invention relates to the field of biomedicine, and discloses an establishment method and application of a diabetes mellitus chronic wound model. A diabetic SD rat is induced through combination of high fat diet and STZ intraperitoneal injection, and a 11cm * 2cm double-pedicel skin flap ischemic wound model is constructed on the back of the diabetic SD rat. The method can simulate the characteristic that the wound surface of a diabetic patient is not healed for a long time due to vasculopathy, and has typical pathological characteristics of wound surface healing delay, continuous inflammatory response, angiogenesis limitation and the like. On the 15th day after the operation, the wound surface is still obviously covered by scab, the wound surface is not completely closed, the inflammatory cell infiltration is more, the wound surface healing speed is obviously slowed down, and the pro-inflammatory factor is still higher, which indicates that the wound surface is continuously in a chronic inflammatory state. The model construction cost is low, the operation is simple and convenient, the condition of delayed healing of the diabetic wound can be more truly represented, and the method has a wide application prospect.

This invention provides the application of transcription factor CUX1 in the preparation of products for the prevention and treatment of diabetic foot ulcers, belonging to the field of biomedical technology. Its key technical point lies in providing the application of transcription factor CUX1 as a target in the preparation of products for the prevention and treatment of diabetic foot ulcers. This application confirms the high expression of transcription factor CUX1 in diabetic foot ulcer wound tissue through specific verification experiments. Using a diabetic rat model of ischemic foot ulcers in the lower limbs, this invention is the first to clearly demonstrate a significant increase in the expression of transcription factor CUX1 in diabetic ulcer wound tissue. Using a high-glucose, high-lipid cell injury model, it is the first to demonstrate that CUX1 expression is significantly high after fibroblast injury due to high glucose and high lipid levels. It is the first to discover that transcription factors have a protective effect on fibroblasts injured by high glucose and high lipid levels. This invention provides a new approach for the treatment of diabetic foot ulcers and a new target for the development of diabetic wound healing.

A copper hydrogen phosphate-loaded hydrogel with pH-responsive multi-enzyme activity, as well as its preparation method and application, is disclosed. In a neutral microenvironment, the material primarily exhibits catalase-like activity, scavenging H2O2 and alleviating oxidative stress. In a weakly acidic microenvironment, it primarily exhibits peroxidase-like activity, catalyzing H2O2 to produce the more toxic ·OH antibacterial compound. Simultaneously, copper's inherent osteogenic properties synergistically enhance bone regeneration. The present invention evaluates the SA / CuHP hydrogel's biocompatibility, antioxidant properties, osteogenic ability under oxidative stress conditions, and antibacterial efficacy under weakly acidic conditions through in vitro experiments. A periodontitis model in type 2 diabetic rats is established to verify its in vivo antibacterial and osteogenic effects and biosafety, providing a new strategy for the treatment of diabetic periodontitis.

The application discloses a new application of mulberry polysaccharide in preparation of a medicine for treating type 2 diabetes by regulating intestinal flora, and belongs to the technical field of medicinal and edible plant polysaccharides. In the application, a type 2 diabetes rat model is constructed by using high-sugar and high-fat feed in combination with streptozotocin, biochemical index detection, liver HE staining and oil red O staining, intestinal flora 16S rRNA high-throughput sequencing, and GC-MS detection of short-chain fatty acid content are carried out, so as to confirm that the mulberry polysaccharide can regulate the intestinal flora structure of T2DM rats, improve the secretion level of short-chain fatty acids, improve insulin resistance and glycolipid metabolism disorder, enhance the antioxidant capacity of the body, and repair the pathological damage of the liver. The application clearly defines the anti-type 2 diabetes mechanism of the mulberry polysaccharide, which takes the intestinal flora-short-chain fatty acid axis as the core. The mulberry polysaccharide is a natural low-toxicity medicinal and edible active ingredient, has no side effects of chemical hypoglycemic drugs, can be prepared into various oral medicine dosage forms, and is used for the prevention and clinical treatment of type 2 diabetes, so the application prospect is wide.

A compound represented by formula (I) and a preparation method thereof, and a pharmaceutically acceptable salt thereof, a metabolic precursor thereof, a metabolite thereof, an isomer thereof or a prodrug thereof; experiments show that the indole alkaloid not only promotes axon growth of peripheral sensory neurons, improves the nerve conduction velocity and anesthesia symptom of diabetic rats, but also promotes healing of foot ulcer wounds of diabetic rats, thus having good therapeutic effects on diabetic complication peripheral neuropathy and diabetic feet; they also show that the indole alkaloid also obviously reduces a degree of pulmonary fibrosis induced by bleomycin in mice, and plays a role in protecting lung tissues.

This invention relates to the field of biomedical technology, and particularly to a method and application for identifying active ingredients for the prevention and treatment of diabetes from non-medicinal Astragalus membranaceus slices. The method includes: first, qualitative and quantitative analysis of the chemical components of Astragalus membranaceus and longan slices; second, evaluation of its hypoglycemic efficacy using a diabetic rat model to verify the effects of Astragalus membranaceus and longan slices in lowering blood sugar, improving insulin resistance, and reducing inflammation; and finally, integration of non-targeted and pseudo-targeted metabolomics technologies to systematically identify the core active ingredients in key pathways for the prevention and treatment of diabetes by analyzing the correlation between chemical components and efficacy indicators. This invention not only reveals the main pharmacodynamic substances of Astragalus membranaceus in the prevention and treatment of diabetes, but also provides a theoretical basis and technical support for the development of related functional products or innovative drugs, and for comprehensively improving the utilization efficiency and economic value of Astragalus membranaceus resources.